CD274 and neoplasm: The final OS data showed no benefit for the intent-to-treat population (HR 0.88, 95% CI 0.73–1.05; P = 0.158), but on secondary analysis for those with high PD-L1 expression (≥50% PD-L1 expression on tumour cells or ≥10% expression on tumour-infiltrating immune cells) there was an apparent benefit in OS (HR 0.48, 95% CI 0.29–0.81).78 In subgroup analyses by age, only available for PFS, a benefit to all three age groups was demonstrated (age < 65 years HR 0.77, 95% CI 0.61–0.99; age 65–74 years HR 0.66, 95% CI 0.51–0.87; age 75–84 years HR 0.51, 95% CI 0.30–0.84).